ECE2020 ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (142 abstracts)
The effect of PCSK9 Inhibitor EVOLOCUMAB on aldosterone among high cardiovascular risk patients
Elena Lzkhakov 1 , Yakov Shacham 2 , Mariana Yaron 2 , Merav Serebro 2 , Karen Tordjman 2 , Yona Greenman 2 & Naftali Stern 2 &Tomer Ziv
1Tel Aviv Sourasky Medical Center, Tel Aviv Univrsity, Institute ofEndocrinology, Metabolism and Hypertension, Tel Aviv, Israel; 2Ichilov, Tel Aviv–Yafo, Israel; 3Tel Aviv University, Tel Aviv–Yafo, Israel
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors decrease the degradation of low–density lipoprotein (LDL) receptors, thereby increasing the removal of LDL particles from the blood and significantly reducing LDL cholesterol levels by an average of 65%. Blom et al. showed changes in vitamin E, adrenocorticotropic hormone (ACTH), cortisol, total testosterone, and estradiol in EVOLOCUMAB (PCSK9 inhibitor)–treated patients 1. There are currently no published data on the impact of PCSK9 inhibitor monotherapy on aldosterone.
Aim of the study: To examine the effect of EVOLOCUMAB monotherapy on LDL cholesterol reduction and steroidogenesis in high cardiovascular risk patients with statin intolerance.
Methods: Lipid profile, sodium, potassium, aldosterone, cortisol, and ACTH were analyzed at baseline and after 3 months of EVOLOCUMAB therapy. Each participant underwent two dynamic tests, a 250 mg ACTH test and an ambulation test, on two consecutive days at the beginning and end of the study.
Results: Fifteen patients were included in the study. Total cholesterol, LDL cholesterol, lipoprotein (a), and stimulated aldosterone levels were significantly lower after 3 months of EVOLOCUMAB therapy. There were no significant changes in ACTH, cortisol, or potassium levels.
Conclusions: Reduction in stimulated aldosterone secretion by EVOLOCUMAB treatment could theoretically be associated with the reduction of cardiovascular events, and that possibility warrants further investigation.
Reference:
1. Blom DJ, Djedjos CS, Monsalvo ML, Bridges I, Wasserman SM, Scott R, Roth E. Effects of Evolocumab on Vitamin E and Steroid Hormone Levels Results From the 52–Week, Phase 3, Double-Blind, Randomized, Placebo–Controlled DESCARTES Study. Circ Res. 2015 Sep 25 117(8) 731–41.
Volume 70
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more